Overview

Efficacy and Safety of Low Dose Thalidomide in Transfusion Dependent Thalassemia

Status:
Recruiting
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
Thalidomide is known to have hypnosedative, immuno-modulatory and anti-angiogenic effects. The drug is widely used in several neoplastic disorders (e.g. multiple myeloma and malignant melanoma), inflammatory conditions (e.g. Crohn's disease) and skin disorders (e.g. leprosy). Thalidomide has been successfully used in adult thalassemia patients. The current study explores its role in younger thalassemia patients.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Blood Diseases Clinic
Treatments:
Thalidomide